Browsing by Author Mauro Schechter

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)
1-Oct-2016Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 TargetsJean B. Nachega; Olatunji Adetokunboh; Olalekan A. Uthman; Amy W. Knowlton; Frederick L. Altice; Mauro Schechter; Omar Galárraga; Elvin Geng; Karl Peltzer; Larry W. Chang; Gilles Van Cutsem; Shabbar S. Jaffar; Nathan Ford; Claude A. Mellins; Robert H. Remien; Edward J. Mills; University of Pittsburgh Graduate School of Public Health; Universiteit Stellenbosch; Johns Hopkins University; Warwick Medical School; Yale University School of Medicine; Projeto Praça Onze; Brown University; University of California, San Francisco; Mahidol University; University of Limpopo; Human Sciences Research Council of South Africa; Médecins Sans Frontières; Liverpool School of Tropical Medicine; Organisation Mondiale de la Sante; Columbia University in the City of New York; New York State Psychiatric Institute; Precision Global Health
1-Jun-2006Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and CameroonSwati B. Gupta; Christopher T. Mast; Nathan D. Wolfe; Vlad Novitsky; Sheri A. Dubey; Esper G. Kallas; Mauro Schechter; Bernard Mbewe; Eftyhia Vardas; Punee Pitisuttithum; Donald Burke; Dan Freed; Robin Mogg; Paul M. Coplan; Jon H. Condra; Romnie S. Long; Kiersten Anderson; Danilo R. Casimiro; John W. Shiver; Walter L. Straus; Merck & Co., Inc.; Johns Hopkins Bloomberg School of Public Health; Harvard School of Public Health; Universidade Federal de Sao Paulo; Universidade Federal do Rio de Janeiro; Malawi College of Medicine; Ministry of Population and Health; University of Witwatersrand; Mahidol University; Intl. Partnership for Microbicides; Merck Research Laboratories
1-May-2005Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continentsPaul M. Coplan; Swati B. Gupta; Sheri A. Dubey; Punnee Pitisuttithum; Alex Nikas; Bernard Mbewe; Efthyia Vardas; Mauro Schechter; Esper G. Kallas; Dan C. Freed; Tong Ming Fu; Christopher T. Mast; Pilaipan Puthavathana; James Kublin; Kelly Brown Collins; John Chisi; Richard Pendame; Scott J. Thaler; Glenda Gray; James Mcintyre; Walter L. Straus; Jon H. Condra; Devan V. Mehrotra; Harry A. Guess; Emilio A. Emini; John W. Shiver; Merck Research Laboratories; Mahidol University; Malawi College of Medicine; Ministry of Population and Health; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo; University of Witwatersrand; Intl. Partnership for Microbicides; The University of North Carolina at Chapel Hill; International AIDS Vaccine Initiative; International Partnership for Microbicides
22-Jan-2010International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trialsT. Christopher Mast; Lisa Kierstead; Swati B. Gupta; Alexander A. Nikas; Esper G. Kallas; Vladimir Novitsky; Bernard Mbewe; Punee Pitisuttithum; Mauro Schechter; Eftyhia Vardas; Nathan D. Wolfe; Miguel Aste-Amezaga; Danilo R. Casimiro; Paul Coplan; Walter L. Straus; John W. Shiver; Merck Research Laboratories; Universidade Federal de Sao Paulo; Harvard School of Public Health; Malawi College of Medicine; Mahidol University; Universidade Federal do Rio; University of Witwatersrand; Johns Hopkins Bloomberg School of Public Health
1-Apr-2008Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugsCarlo Federico Perno; Graeme Moyle; Chris Tsoukas; Winai Ratanasuwan; Jose Gatell; Mauro Schechter; Universita degli Studi di Roma Tor Vergata; Chelsea and Westminster Hospital; McGill University Health Centre, Montreal General Hospital; Mahidol University; Universitat de Barcelona; Universidade Federal do Rio de Janeiro
1-Jun-2008Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infectionGraeme Moyle; Jose Gatell; Carlo Federico Perno; Winai Ratanasuwan; Mauro Schechter; Christos Tsoukas; Chelsea and Westminster Hospital; Universitat de Barcelona; Universita degli Studi di Roma La Sapienza; Mahidol University; Universidade Federal do Rio de Janeiro; McGill University
1-Jul-2004Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudinePedro Cahn; Asda Vibhagool; Mauro Schechter; Luis Soto-Ramirez; Giampiero Carosi; Fiona Smaill; Jamie C. Jordan; Cristina E. Pharo; Nicola E. Thomas; Helen M. Steel; Fundacion Huesped; Mahidol University; Universidade Federal do Rio de Janeiro; Instituto Nacional de la Nutricion Salvador Zubiran; Universita degli Studi di Brescia; McMaster University Medical Centre; GlaxoSmithKline, USA; GlaxoSmithKline plc, United Kingdom
1-Jul-2004Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: Results of a 48-week open-label, equivalence trial (CNA3014)Asda Vibhagool; Pedro Cahn; Mauro Schechter; Fiona Smaill; Luis Soto-Ramirez; Giampiero Carosi; Maria Montroni; Cristina E. Pharo; Jamie C. Jordan; Nicola E. Thomas; Gill Pearce; Mahidol University; Fundacion Huesped; Universidade Federal do Rio de Janeiro; McMaster University Medical Centre; Instituto Nacional de la Nutricion Salvador Zubiran; Clin. Malat. Infettive e Tropicalli; Ospedale Umberto I, Ancona; GlaxoSmithKline plc, United Kingdom; GlaxoSmithKline, USA